Obtaining an accurate diagnosis of Parkinson’s disease, particularly early in the disease continuum, is a difficult, yet crucial, component needed to provide effective treatment for Parkinson’s disease patients.
While there is no single test for Parkinson’s disease, there are several symptoms and diagnostic tools that can be used in combination to diagnose Parkinson’s disease.
Below, we provide a high-level overview of how Parkinson’s disease is diagnosed, highlighting current clinical diagnostic criteria, available imaging tests, and the path toward early and accurate Parkinson’s disease diagnosis.
Currently, there is no single test for Parkinson’s disease—no brain scan or lab test (e.g. blood, cerebrospinal fluid, and urine) can provide a definitive diagnosis of Parkinson’s disease. Instead, doctors diagnose Parkinson’s disease “clinically,” meaning a diagnosis is dependent on medical history, answers to certain questions, a physical examination, and the presence of specific physical symptoms.
Typically, the process for diagnosing Parkinson’s disease follows these general steps:
Clinical diagnosis of Parkinson’s disease, or any disease for that matter, relies heavily on the doctor’s judgment and expertise. Oftentimes, the patient’s symptoms, along with the neurological examination, are sufficient for determining the correct diagnosis, particularly for patients in the later stages of the disease. However, doctors may suggest further testing, such as brain imaging, to rule out any conditions that mimic the symptoms of Parkinson’s disease (Parkinson’s syndrome).
As we continue to see advancements in neuroscience, and researchers continue to deepen our understanding of Parkinson’s disease, clinical diagnostic criteria will continue to evolve to better support more accurate diagnosis.
Currently, Parkinson’s disease is considered likely in patients who exhibit two or more of the four main symptoms of Parkinson’s disease:
Currently, for diagnosis, many doctors use the gold standard checklist created by the UK Parkinson’s Disease Society Brain Bank. However, recently, a new set of diagnostic criteria created by the International Parkinson and Movement Disorder Society has come into use. This also included the first-ever criteria for prodromal Parkinson’s disease.
While no lab or imaging test can definitively diagnose Parkinson’s disease, several helpful imaging tools can be used to support Parkinson’s disease diagnosis.
For example, while not approved by the FDA for Parkinson’s disease diagnosis, positron emission tomography (PET) scans are often used during the diagnostic process to rule out other conditions.
Individuals with Parkinson’s disease experience dopamine deficits in the striatum resulting from the destruction of dopaminergic (dopamine-producing) neurons located in the substantia nigra. A dopamine transporter scan (DaTscan), a specific single-photon emission computerized tomography (SPECT) scan, can be used to visualize the dopaminergic neurons.
For this test, a radioactive tracer is injected into the bloodstream, where it then circulates around the body, making its way to the brain. The drug binds to dopamine transmitters in the brain, producing detailed pictures of the dopamine system in the brain. Not everyone with suspected Parkinson’s disease will require this test, but it can help distinguish between other functional movement disorders, such as essential tremor.
Like Alzheimer’s disease and many other neurological diseases, Parkinson’s disease begins long before symptoms arise. The benefits of early diagnosis of such diseases are immense and not only affect patients and their families but also the wider society and research community.
Research efforts surrounding Parkinson’s disease risk factors, early symptoms, traditional biomarkers, and digital biomarkers will pave the way for an earlier, more accurate diagnosis. Our growing understanding of the factors involved in Parkinson’s disease risk, development, and progression opens the door to more robust and sensitive testing and diagnostic approaches.
At Altoida, we are dedicated to providing a reliable, affordable, and highly accurate way to measure and monitor brain health. We are building the world’s-first Precision Neurology platform and app-based medical device—backed by 11 years of clinical validation—to accelerate and improve drug development, neurological disease research, and patient care.
By completing a 10-minute series of augmented reality and motor activities designed to simulate complex Activities of Daily Living on a smartphone or tablet, Altoida’s device extracts and provides robust measurements of neurocognitive function across 13 neurocognitive domains. Our device measures and analyzes nearly 800 multimodal cognitive and functional digital biomarkers. Through the collection of highly granular data from integrated smartphone or tablet sensors, Altoida’s device produces comprehensive neurocognitive domain scores. This data can be tracked longitudinally to reveal trends and patterns while flagging concerning ones.
This method, along with our innovative artificial intelligence, will pioneer fully digital predictive neurological disease diagnosis. Recently receiving Breakthrough Device designation by the FDA, Altoida's platform has demonstrated ability to predict conversion from Mild Cognitive Impairment to Alzheimer's disease with a high degree of accuracy.
Currently, we are working to enable early and accurate diagnosis of neurodegenerative diseases like Parkinson's. Our AI-powered technology will be used to monitor disease progression as well as to measure therapeutic response in patients.
To learn more about if there is a test for Parkinson’s disease or about utilizing Altoida’s Precision Neurology platform, contact us today.